MX2019007262A - Compuestos antivirales de bencilamina fosfodiamida. - Google Patents

Compuestos antivirales de bencilamina fosfodiamida.

Info

Publication number
MX2019007262A
MX2019007262A MX2019007262A MX2019007262A MX2019007262A MX 2019007262 A MX2019007262 A MX 2019007262A MX 2019007262 A MX2019007262 A MX 2019007262A MX 2019007262 A MX2019007262 A MX 2019007262A MX 2019007262 A MX2019007262 A MX 2019007262A
Authority
MX
Mexico
Prior art keywords
compounds
antiviral
benzyl
amine
phosphodiamide
Prior art date
Application number
MX2019007262A
Other languages
English (en)
Inventor
RAHEEM Izzat
De Lera Ruiz Manuel
J Hartingh Timothy
Schreier John
Laurent Paparin Jean-
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2019007262A publication Critical patent/MX2019007262A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de la Fórmula I: (Ver Fórmula) y sus sales farmacéuticamente aceptables que son de utilidad para la inhibición de transcriptasa inversa de VIH. Los compuestos también pueden ser de utilidad para la profilaxis o tratamiento de infección por VIH y en la profilaxis, retraso en la aparición o progresión, y tratamiento de SIDA. Los compuestos y sus sales pueden emplearse como ingredientes en composiciones farmacéuticas, opcionalmente en combinación con otros agentes antivirales, inmunomoduladores, antibióticos o vacunas.
MX2019007262A 2016-12-22 2017-12-19 Compuestos antivirales de bencilamina fosfodiamida. MX2019007262A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437745P 2016-12-22 2016-12-22
US201762540748P 2017-08-03 2017-08-03
PCT/US2017/067159 WO2018118826A1 (en) 2016-12-22 2017-12-19 Antiviral benzyl-amine phosphodiamide compounds

Publications (1)

Publication Number Publication Date
MX2019007262A true MX2019007262A (es) 2019-09-05

Family

ID=62627287

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007262A MX2019007262A (es) 2016-12-22 2017-12-19 Compuestos antivirales de bencilamina fosfodiamida.

Country Status (12)

Country Link
US (1) US11123355B2 (es)
EP (1) EP3558322B1 (es)
JP (1) JP2020504734A (es)
KR (1) KR20190100249A (es)
CN (1) CN110035760A (es)
AU (1) AU2017378893A1 (es)
BR (1) BR112019012511A2 (es)
CA (1) CA3046029A1 (es)
MA (1) MA47131A (es)
MX (1) MX2019007262A (es)
RU (1) RU2019122625A (es)
WO (1) WO2018118826A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10745428B2 (en) 2015-12-10 2020-08-18 Idenix Pharmaceuticals Llc Antiviral phosphodiamide prodrugs of tenofovir
EP3390413B1 (en) 2015-12-15 2020-08-19 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
US10449208B2 (en) 2016-08-25 2019-10-22 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
CR20190181A (es) 2016-10-14 2019-08-21 Prec Biosciences Inc Meganucleasas diseñadas específicamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b.
US10736908B2 (en) 2016-10-26 2020-08-11 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
AU2017378893A1 (en) 2016-12-22 2019-05-16 Idenix Pharmaceuticals Llc Antiviral benzyl-amine phosphodiamide compounds
CN110099912B (zh) 2016-12-22 2021-10-15 默沙东公司 抗病毒替诺福韦脂肪族酯前药
AU2018392212B9 (en) 2017-12-20 2021-03-18 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
EP3774883A1 (en) 2018-04-05 2021-02-17 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
CA3093888A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
WO2020018399A1 (en) 2018-07-19 2020-01-23 Merck Sharp & Dohme Corp. Phosphinic amide prodrugs of tenofovir
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
IL282535B2 (en) 2018-10-31 2024-05-01 Gilead Sciences Inc Transformed 6-azabanzimidazole compounds as HPK1 inhibitors
CA3116347A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
BR112021014576A2 (pt) 2019-01-25 2021-10-05 Brown University Composições e métodos para tratamento, prevenção ou reversão de inflamação e distúrbios associados à idade
KR20210137517A (ko) 2019-03-07 2021-11-17 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
CN113574063A (zh) 2019-03-07 2021-10-29 捷克共和国有机化学与生物化学研究所 3’3’-环二核苷酸及其前药
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
PE20220231A1 (es) 2019-06-25 2022-02-07 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso
CN110441453B (zh) * 2019-08-14 2022-03-15 国家烟草质量监督检验中心 一种分离检测磷胺异构体的方法
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
PE20221111A1 (es) 2019-09-30 2022-07-11 Gilead Sciences Inc Vacunas para vhb y metodos de tratamiento de vhb
EP4069729A1 (en) 2019-12-06 2022-10-12 Precision BioSciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
CN111157638A (zh) * 2019-12-31 2020-05-15 济南康和医药科技有限公司 一种检测维生素c中草酸含量的方法
CA3169348A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
JP2023536663A (ja) 2020-08-07 2023-08-28 ギリアード サイエンシーズ， インコーポレイテッド ホスホンアミドヌクレオチド類似体のプロドラッグ及びその薬学的使用
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
TW202348237A (zh) 2021-05-13 2023-12-16 美商基利科學股份有限公司 TLR8調節化合物及抗HBV siRNA療法之組合
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11926628B2 (en) 2021-06-23 2024-03-12 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022299051A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023196832A2 (en) * 2022-04-06 2023-10-12 Brii Biosciences, Inc. Pharmaceutical composition and method for treatment of human immunodeficiency virus infections

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4086314B2 (ja) 1993-09-17 2008-05-14 ギリアード サイエンシーズ， インコーポレイテッド ヌクレオチドアナログ
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en) * 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
CN1740182A (zh) 1999-12-22 2006-03-01 症变治疗公司 新的双氨基化膦酸酯前药
CN100402539C (zh) * 2000-07-21 2008-07-16 吉里德科学公司 核苷酸膦酸酯类似物前药及其筛选和制备方法
US7388002B2 (en) 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
CN105596356A (zh) 2003-01-14 2016-05-25 吉里德科学公司 用于联合抗病毒治疗的组合物和方法
PL1716162T3 (pl) * 2003-12-30 2011-02-28 Gilead Sciences Inc Fosfoniany, manofosfonamidy i bisfosfonamidy do leczenia chorób wirusowych
CA2585353A1 (en) 2004-10-26 2006-05-04 Gilead Sciences, Inc. Phosphonate derivatives of mycophenolic acid
WO2007002912A2 (en) 2005-06-29 2007-01-04 Gilead Sciences, Inc. Anti-proliferative compounds, compositions, and methods of use thereof
JP5356228B2 (ja) 2006-07-07 2013-12-04 ギリアード サイエンシーズ， インコーポレイテッド ｔｏｌｌ様レセプター７の調節因子
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
BR112012024661A2 (pt) 2010-04-01 2015-09-15 Centre Nat Rech Scient composto, composição farmacêutica e método de tratamento de um hospedeiro infectado com vírus de hepatite c
US9120781B2 (en) 2010-05-11 2015-09-01 Simon Fraser University Selective glycosidase inhibitors and uses thereof
WO2012154321A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
MX336627B (es) 2011-08-16 2016-01-26 Gilead Sciences Inc Hemifumarato de tenofovir alafenamida.
JP6113185B2 (ja) 2011-12-22 2017-04-12 ジェロン・コーポレーションＧｅｒｏｎ Ｃｏｒｐｏｒａｔｉｏｎ テロメラーゼ基質およびテロメア長作用因子としてのグアニンアナログ
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
CN103435672A (zh) * 2013-04-25 2013-12-11 刘沛 含有取代苄基的新型核苷磷酸酯前药的结构与合成
PL3194411T3 (pl) 2014-09-15 2022-06-20 The Regents Of The University Of California Analogi nukleotydów
WO2017007701A1 (en) 2015-07-07 2017-01-12 Merck Sharp & Dohme Corp. Antiviral phosphodiamide compounds
EA035028B1 (ru) 2015-08-10 2020-04-20 Мерк Шарп И Доум Корп. Противовирусные фосфодиамидные сложноэфирные бета-аминокислотные соединения
CN106167504A (zh) 2015-11-04 2016-11-30 洛阳聚慧医药科技有限公司 非环核苷磷酰胺d‑氨基酸酯衍生物及其盐的制备以及在抗病毒方面的应用
US10745428B2 (en) 2015-12-10 2020-08-18 Idenix Pharmaceuticals Llc Antiviral phosphodiamide prodrugs of tenofovir
EP3390413B1 (en) 2015-12-15 2020-08-19 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
US10449208B2 (en) 2016-08-25 2019-10-22 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
US10736908B2 (en) 2016-10-26 2020-08-11 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
AU2017378893A1 (en) 2016-12-22 2019-05-16 Idenix Pharmaceuticals Llc Antiviral benzyl-amine phosphodiamide compounds
CN110099912B (zh) 2016-12-22 2021-10-15 默沙东公司 抗病毒替诺福韦脂肪族酯前药

Also Published As

Publication number Publication date
CA3046029A1 (en) 2018-06-28
MA47131A (fr) 2021-05-12
US20190321380A1 (en) 2019-10-24
EP3558322A1 (en) 2019-10-30
EP3558322B1 (en) 2021-09-29
JP2020504734A (ja) 2020-02-13
RU2019122625A (ru) 2021-01-22
BR112019012511A2 (pt) 2019-11-19
AU2017378893A1 (en) 2019-05-16
WO2018118826A1 (en) 2018-06-28
CN110035760A (zh) 2019-07-19
US11123355B2 (en) 2021-09-21
KR20190100249A (ko) 2019-08-28
EP3558322A4 (en) 2020-05-06

Similar Documents

Publication Publication Date Title
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
PH12018500292A1 (en) Antiviral beta-amino acid ester phosphodiame compounds
MX2019007585A (es) Profarmacos de ester alifatico antiviricos de tenofovir.
PH12015500764B1 (en) 5-phenoxy-3h-pyrimidin-4-one derivatives and their use as hiv reverse transcriptase inhibitors
TN2012000455A1 (en) Non-nucleoside reverse transcriptase inhibitors
NZ724343A (en) 4’-substituted nucleoside-derivatives as hiv reverse transcriptase inhibitors
TN2009000243A1 (en) Non-nucleoside reverse transcriptase inhibitors
CA2998646C (en) 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
MX2016012915A (es) Profarmacos de inhibidores de la transcriptasa inversa del virus de la inmunodeficiencia humana (vih).
EA201170537A1 (ru) Ингибиторы вич-интегразы